Genmab reported DKK407M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Agios Pharmaceuticals USD -110.55M 527K Jun/2026
Almirall EUR 71.55M 41.32M Jun/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.68B 65M Sep/2026
argenx SE USD 486M 7M Sep/2026
AstraZeneca USD 4.66B 1.5B Sep/2026
Bayer EUR 129M 698M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Demant DKK 2.12B 35M Jun/2026
Exelixis USD 268.42M 20.01M Sep/2026
Fresenius Medical Care EUR 384M 153.27M Sep/2026
Genmab DKK 407M 182M Jun/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
GN Store Nord DKK 310M 252M Sep/2026
GRIFOLS EUR 394M 65M Sep/2026
Hikma Pharmaceutical USD 348M 161M Dec/2025
Insmed USD -81.83M 19.48M Sep/2026
Lakefront Biotherapeutics EUR -41.17M 2.34M Sep/2026
Lonza CHF 673M 243M Jun/2025
Merck EUR 660M 437M Sep/2026
Novartis USD 5.14B 392M Sep/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
UCB EUR 1.29B 571M Dec/2025